Your browser doesn't support javascript.
loading
Engineering of a GLP-1 analogue peptide/anti-PCSK9 antibody fusion for type 2 diabetes treatment.
Chodorge, Matthieu; Celeste, Anthony J; Grimsby, Joseph; Konkar, Anish; Davidsson, Pia; Fairman, David; Jenkinson, Lesley; Naylor, Jacqueline; White, Nicholas; Seaman, Jonathan C; Dickson, Karen; Kemp, Benjamin; Spooner, Jennifer; Rossy, Emmanuel; Hornigold, David C; Trevaskis, James L; Bond, Nicholas J; London, Timothy B; Buchanan, Andrew; Vaughan, Tristan; Rondinone, Cristina M; Osbourn, Jane K.
Afiliação
  • Chodorge M; Antibody Discovery and Protein Engineering, MedImmune, Cambridge, UK. ChodorgeM@medimmune.com.
  • Celeste AJ; Biosuperiors, MedImmune, Gaithersburg, USA.
  • Grimsby J; Cardiovascular, Renal and Metabolic diseases, MedImmune, Gaithersburg, USA. GrimsbyJ@medimmune.com.
  • Konkar A; Cardiovascular, Renal and Metabolic diseases, MedImmune, Gaithersburg, USA.
  • Davidsson P; Cardiovascular and Metabolic diseases, Innovative Medicines and Early Development Biotech unit, Translational Science, AstraZeneca R&D, Gothenburg, Sweden.
  • Fairman D; Clinical Pharmacology and DMPK, MedImmune, Cambridge, UK.
  • Jenkinson L; Antibody Discovery and Protein Engineering, MedImmune, Cambridge, UK.
  • Naylor J; Cardiovascular, Renal and Metabolic diseases, MedImmune, Cambridge, UK.
  • White N; Clinical Pharmacology and DMPK, MedImmune, Cambridge, UK.
  • Seaman JC; Antibody Discovery and Protein Engineering, MedImmune, Cambridge, UK.
  • Dickson K; Biopharmaceutical Development, MedImmune, Cambridge, UK.
  • Kemp B; Antibody Discovery and Protein Engineering, MedImmune, Cambridge, UK.
  • Spooner J; Antibody Discovery and Protein Engineering, MedImmune, Cambridge, UK.
  • Rossy E; Biopharmaceutical Development, MedImmune, Cambridge, UK.
  • Hornigold DC; Cardiovascular, Renal and Metabolic diseases, MedImmune, Cambridge, UK.
  • Trevaskis JL; Cardiovascular, Renal and Metabolic diseases, MedImmune, Gaithersburg, USA.
  • Bond NJ; Biopharmaceutical Development, MedImmune, Cambridge, UK.
  • London TB; Antibody Discovery and Protein Engineering, MedImmune, Cambridge, UK.
  • Buchanan A; Antibody Discovery and Protein Engineering, MedImmune, Cambridge, UK.
  • Vaughan T; Antibody Discovery and Protein Engineering, MedImmune, Cambridge, UK.
  • Rondinone CM; Cardiovascular, Renal and Metabolic diseases, MedImmune, Gaithersburg, USA.
  • Osbourn JK; Biosuperiors, MedImmune, Cambridge, UK.
Sci Rep ; 8(1): 17545, 2018 12 03.
Article em En | MEDLINE | ID: mdl-30510163
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteínas Recombinantes de Fusão / Diabetes Mellitus Experimental / Diabetes Mellitus Tipo 2 / Peptídeo 1 Semelhante ao Glucagon / Inibidores de PCSK9 / Hipoglicemiantes / Anticorpos Monoclonais Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Animals / Humans / Male Idioma: En Revista: Sci Rep Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteínas Recombinantes de Fusão / Diabetes Mellitus Experimental / Diabetes Mellitus Tipo 2 / Peptídeo 1 Semelhante ao Glucagon / Inibidores de PCSK9 / Hipoglicemiantes / Anticorpos Monoclonais Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Animals / Humans / Male Idioma: En Revista: Sci Rep Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Reino Unido